PER-075-14招募中未知
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THESAFETY AND EFFICACY OF BMS-931699 VS. PLACEBO ON A BACKGROUND OF LIMITED STANDARD OF CAREIN THE TREATMENT OF SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 70（—）
入选标准
- •1) SLE defined by 4 of 11 classification criteria of ACR for SLE (sequentially or coincidently). 2)Subjects must have elevated ANA > to 1:80 via immunofluorescent assay and/or positive anti-dsDNA or anti-Sm above the normal level (all determined by the central laboratory). 3)Subjects must have a SLEDAI greater or equal to 6. At least 4 of the points must be attributable to clinical criteria. Must be confirmed by External Adjudication Committee. 4)Subjects must have at least one of the following manifestations of SLE, which must be confirmed by the External Adjudication committee: BILAG A or B score in the Mucocutaneous body system or BILAG A or B score in the Musculoskeletal body system due to active polyarthritis as defined in protocol. 5) Subjects must be currently receiving at least one of the following: (1)Administration for a minimum of 12 weeks, and a stable dose for at least 56 days (8 weeks) prior to signing consent, of the following steroid sparing agents are permitted: azathioprine (AZA), chloroquine, hydroxychloroquine or methotrexate (MTX) and, (2)Prednisone (or prednisone-equivalent) cannot exceed 30mg/day at screening for a subject to be eligible and must be stable at a maximum of 10 mg/day for at least 5 days prior to Day 1.
排除标准
- •1) Sujetos con LES inducida por farmacos, en lugar de LES idiopatica. 2) Sujetos con otra enfermedad autoinmune. 3) Sujetos con sindrome de anticuerpos antifosfolipido primario como rasgo unico o principal de su LES o sindrome simlar a LES. 4) Sujetos con antecedentes o riesgo para la tuberculosis (TB). 5) Los sujetos con manifestaciones neuropsiquiatricas del lupus activa o inestables y sujetos con nefritis lupica grave activa (OMS clase III, IV). Nota: Se permite re-enrolamientos de pacientes
研究者
相似试验
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2012-003123-38-HUCelgene International II Sàrl (CIS II).113
已完成
2 期
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS10017969Ulcerative colitisNL-OMON47857Celgene International II Sarl (CIS II)10
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-003123-38-PLCelgene International II Sàrl (CIS II)86
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2012-003123-38-SKCelgene International II Sàrl (CIS II).86
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2012-003123-38-BECelgene International II Sàrl (CIS II)86